Formulation, Statistical Optimization and In Vitro Evaluation of Transdermal Anastrozole Nanospanlastic

In postmenopausal women, anastrozole reduces estrogen levels, which may inhibit the development of certain breast cancers that need estrogen to increase in the body. The limitations of anastrozole are the first-pass action, limited aqueous solubility, and gastrointestinal issues. Additionally, improving skin permeability, controlling drug release, and shielding sensitive molecules from deterioration are just a few of the uses for nanoparticles that are gaining popularity. Spanlastics are elastic, malleable nanovesicles based on surfactants. They comprise an edge activator (EA) and a nonionic surfactant. In this study, anastrozole nanospanlastic (Ana-SPLs) was created to improve patient compliance and control anastrozole transdermal distribution as an alternative to the oral route. Therefore, the study aimed to develop a formulation that could get around these problems by using the advantages of the transdermal administration route and nanotechnology concepts. Minimized sizes with higher absolute zeta potential Ana-SPLs were formulated using a response-surface randomized User-Defind method. In addition to one category component that addresses the kind of EA, two numerical variables were examined: Span 60 to EA ratio (w/w) and sonication duration (min). Zeta potential (mV) and particle size (nm) were investigated as responses. A mathematical optimization technique was used to forecast the optimal variable values. With a sonication period of 5 minutes, the optimized formulation with a Span 60: SDC ratio of 9:1 w/w revealed particle dimensions of 128 nm with a zeta potential of -32 mV. Formula (F2) was seen using transmission electron microscopy to have a homogeneous, spherical shape. Because of its tiny particle size, high entrapment efficiency percentage (80.2 ± 4.3%), and 12-hour release pattern, formula (F2) was selected for further analysis. The compatibility study did not consider the interaction of Ana with other components. The previously described findings suggest spanlastics may be potentially effective drug carriers for transdermal medication administration.